ClinicalTrials.gg
Active, not recruitingNCT06510816ARCHER IIUpdated Oct 6, 2026

A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA)

A Phase 3 interventional study of Vonaprument and Sham Administration in Geographic Atrophy, sponsored by Annexon, Inc.. Active, not recruiting at 132 sites in 14 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by Annexon, Inc. · Phase 3, Interventional, and Treatment

Updated Oct 6, 2026Primary completion movedPrimary outcomes revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
659
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 131 studies in Geographic Atrophy with a site in United States — 35 open to participants now, 45 under way, 5 of them phase 3. Geographic Atrophy · United States.

Enrollment
7th of 107
659 · median 98
Started
2024
with 4 others
Phase 3
15 of 131
2 open now
Primary completion
2027-07
later than 15 of 44 live
Registered
99th of 131
by date
Lead sponsor
3 of 131
Annexon, Inc.

Among the 131 studies in Geographic Atrophy with a site in United States, this one is the 7th largest by enrollment of the 107 interventional ones that give a count, is one of 5 that started in 2024, is one of 15 in phase 3, reaches primary completion later than 15 of the 44 other live ones, and was the 99th registered.

Geographic Atrophy

188 studies on the registry are indexed under Geographic Atrophy; 52 are open to participants now.

Browse Geographic Atrophy studies →

Open to participants now

35 of the 131 studies in Geographic Atrophy with a site in United States are open now. Recruiting first, the newest first:

30 more — sign in →

All 35 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 40 Geographic Atrophy studies recruiting now, 31 (78%) set no upper age limit and none (0%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 131 studies in Geographic Atrophy with a site in United States, or all of them as a file.
02

Study summary

The primary purpose of the study is to determine if IVT injections of vonaprument every month reduce vision loss in participants with dry AMD with GA.

03

Conditions studied

  • Geographic Atrophy

Browse trials for

04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of dry AMD with GA as determined by the Investigator and confirmed by the independent Central Reading Center.

Exclusion criteria

Exclusion Criteria:

  • Geographic atrophy due to other causes than AMD such as Stargardt disease, cone-rod dystrophy, pathologic myopia, or toxic maculopathies (for example, plaquenil maculopathy) in either eye.

NOTE: Other protocol-defined inclusion and exclusion criteria apply.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
659 participants (actual)

Study arms

  • Experimental
    Vonaprument

    Participants will receive vonaprument IVT injections every month during the 24-month treatment period.

    Drug: Vonaprument

  • Sham comparator
    Sham Group

    Participants will receive Sham IVT injections every month during the 24-month treatment period.

    Other: Sham Administration

Interventions

  • Form: solution for injection; Route of Administration: IVT injection

    Also known as: ANX007

  • OtherSham Administration

    Form and Route of Administration: to mimic IVT injection (includes placement of the blunt opening of an empty, needleless syringe barrel on the conjunctiva in the inferotemporal quadrant of the eyeball to stimulate the pressure of an injection).

06

What researchers measure

Primary outcomes

  1. Proportion of Participants Experiencing a Best Corrected Visual Acuity (BCVA) ≥15-letter Loss from Baseline Through Month 15 as Assessed by the Early Treatment Diabetic Retinopathy Study (ETDRS) Chart at Any Two Consecutive Visits

    Time frame: Baseline through Month 15

  2. Proportion of Participants Experiencing a BCVA ≥15-letter Loss from Baseline Through Month 24 as Assessed by the ETDRS Chart at Any Two Consecutive Visits

    Time frame: Baseline through Month 24

Secondary outcomes

  1. Time to Confirmed BCVA ≥15-letter Loss

    Time frame: Baseline to Month 15 and Baseline to Month 24

  2. Proportion of Participants with Low-luminance BCVA (LLVA) ≥15-letter Loss

    Time frame: Baseline through Month 15 and Baseline through Month 24

  3. Change from Baseline in Area of Total Loss of the Ellipsoid Zone (EZ) Layer

    Time frame: Baseline, Month 15 and 24

07

Study locations

132 sites

Showing the first 100 of 132 sites across 14 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Jul 2024 (actual). Primary completion is estimated for Jul 2027, 36 months after the start.

Primary completion moved once since we started tracking on Sep 25, 2026: Oct 2026 → Jul 2027, on Oct 6, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 15, 2024
First posted
Jul 19, 2024
StartActual
Jul 30, 2024
Primary completionEst.
Jul 31, 2027was Oct 2026
CompletionEst.
Jul 31, 2027
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Oct 31, 2026→Jul 31, 2027
Oct 6, 2026
Primary outcomes
1 added
What changed in the outcomes
  • AddedProportion of Participants Experiencing a BCVA ≥15-letter Loss from Baseline Through Month 24 as Assessed by the ETDRS Chart at Any Two Consecutive VisitsTime frame: Baseline through Month 24
Oct 6, 2026
Secondary outcomes
1 removed
What changed in the outcomes
  • RemovedProportion of Participants Experiencing a Confirmed BCVA ≥15-letter LossTime frame: Baseline through Month 24
Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    Primary completion Oct 31, 2026→Jul 31, 2027
    Primary outcomes 1 added
    What changed in the outcomes
    • AddedProportion of Participants Experiencing a BCVA ≥15-letter Loss from Baseline Through Month 24 as Assessed by the ETDRS Chart at Any Two Consecutive VisitsTime frame: Baseline through Month 24
    Secondary outcomes 1 removed
    What changed in the outcomes
    • RemovedProportion of Participants Experiencing a Confirmed BCVA ≥15-letter LossTime frame: Baseline through Month 24
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06510816
Lead sponsor
Annexon, Inc.
Responsible party
Sponsor
First posted
Jul 19, 2024
Start date
Jul 30, 2024
Primary completion
Jul 31, 2027 (estimated)
Completion
Jul 31, 2027 (estimated)
Last update
Oct 6, 2026

Study contacts

Clinical Trials
study director · Annexon, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vonaprument

Start the discussion